Paroxetine: current status in psychiatry

  title={Paroxetine: current status in psychiatry},
  author={C. Pae and A. Patkar},
  journal={Expert Review of Neurotherapeutics},
  pages={107 - 120}
  • C. Pae, A. Patkar
  • Published 2007
  • Medicine
  • Expert Review of Neurotherapeutics
  • Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. It is commercially available in both an immediate-release (paroxetine) and a controlled-release formulation (paroxetine CR). The latter product was developed to improve gastrointestinal tolerability. Paroxetine is the most potent inhibitor of the reuptake of serotonin among the available SSRIs. It has approved indications for the treatment of major depression, obsessive–compulsive… CONTINUE READING
    39 Citations
    Paroxetine: safety and tolerability issues
    • 31
    A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
    • 113
    Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
    • 47
    • PDF
    Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.
    • 74
    • PDF
    Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial.
    • 86
    • PDF
    Effect of comedication of bupropion and other antidepressants on body mass index
    • 5
    Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms.
    • 10


    Paroxetine Controlled Release
    • 26
    Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    • 107
    Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
    • 113